COMMUNIQUÉS West-GlobeNewswire

Transactions in connection with share buy-back program
13/10/2026
Company announcement no. 39 - 26 13 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Travelan® Phase 2 Study Results Published
13/10/2026
MELBOURNE, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan ® has been published in the Nature [...]
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
13/10/2026
- An additional five years of patent protection may be possible through a standard extension - PURCHASE, N.Y., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Company” or “Cognition”) (NASDAQ: [...]
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
13/10/2026
New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing LOUISVILLE, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading [...]
Le Gala Reale Di Savoia fera ses débuts à Montréal au profit de la Fondation Point d’Appui
13/10/2026
Une soirée d’exception réunissant philanthropie, histoire et impact communautaire en présence de Son Altesse Royale le prince Emanuele Filiberto de Savoie MONTRÉAL, 13 oct. 2026 (GLOBE NEWSWIRE) -- Une tradition [...]
Gala Reale di Savoia to make It’s Montreal debut in support of Point d’Appui Foundation
13/10/2026
A distinguished evening that will unite philanthropy, history and community impact in the presence of His Royal Highness Prince Emanuele Filiberto di Savoia MONTREAL, Oct. 13, 2026 (GLOBE NEWSWIRE) -- A centuries-old [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
13/10/2026
Company Announcement Net sales of DARZALEX ® in the third quarter of 2026 totaled USD 4,239 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc [...]
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
13/10/2026
AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with pembrolizumab alone The [...]
Leo International Precision Health AG implements capital increase from company reserves
13/10/2026
Planegg / Martinsried, October 13, 2026 – Leo International Precision Health AG (“LIPH”, ticker symbol: LEOW), a holding company building a global integrated AI-driven healthcare ecosystem, is implementing the technical [...]
Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress Update
13/10/2026
Oslo, 13 October 2026 – Zelluna (OSE: ZLNA), a clinical-stage biotechnology Company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, will publish its [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China
13/10/2026
BEIJING, Oct. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
12/10/2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE [...]
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
12/10/2026
– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axatilimab continues to [...]
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
12/10/2026
AUDUBON, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2026 after [...]
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
12/10/2026
NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative [...]

Pages